Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature-Reference-Cited by-同舟云学术

Prolonged complete remission of metastatic HER2-positive breast cancer after continuous trastuzumab treatment: a case report and review of the literature

Published:2014-12-17 Issue:2 Volume:10 Page:297-301
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Ihnenfeld Arciénega Isabel,Imesch Patrick,Fink Daniel,Dedes Konstantin J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-014-0350-9.pdf

Reference27 articles.

1. Swain SM, Kim SB, Cortes J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14(6):461–471. doi: 10.1016/S1470-2045(13)70130-X

2. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, Group CS (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119. doi: 10.1056/NEJMoa1113216

3. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269–280. doi: 10.1038/ncponc0509

4. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol Off J Am Soc Clin Oncol 28(1):92–98. doi: 10.1200/JCO.2008.19.9844

5. Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC (2013) Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141(3):507–514. doi: 10.1007/s10549-013-2711-y

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of Trastuzumab Emtansine in treating human epidermal growth factor receptor 2-positive metastatic breast cancer in Chinese population: a real-world multicenter study;Frontiers in Medicine;2024-04-29

2. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018;Breast Cancer Research and Treatment;2022-07-22

3. Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?;Clinical Breast Cancer;2021-12

4. Anti-HER2 antibody therapy using gene-transduced adipocytes for HER2-positive breast cancer;Breast Cancer Research and Treatment;2020-03-02

5. Research priorities in metastatic breast cancer: A James Lind Alliance Priority Setting Partnership;The Breast Journal;2020-03